Search

Displaying results 5231 - 5240 of 10000 in total
  1. Drug

    Astegolimab

    go.drugbank.com/drugs/DB16386
    Investigational

    Astegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).

  2. Drug

    Cilgavimab

    go.drugbank.com/drugs/DB16393
    ApprovedInvestigational

    [A243356, A243361] Cilgavimab (formerly AZD1061) is a recombinant monoclonal antibody produced in Chinese hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural … SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2).

  3. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    [A243356, A243361] Tixagevimab (formerly AZD8895) is a recombinant monoclonal antibody produced in Chinese hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a … SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2).

  4. Drug

    Pidacmeran

    go.drugbank.com/drugs/DB16401
    Investigational

    Pidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).

  5. Drug

    Geptanolimab

    go.drugbank.com/drugs/DB16417
    Investigational

    Geptanolimab is under investigation in clinical trial NCT03502629 (Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)).

  6. Drug

    AK119

    go.drugbank.com/drugs/DB16423
    Investigational

    AK119 is a humanized anti-CD73 monoclonal antibody being investigated in the clinical trial NCT04516564 (A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects).[L28315]

  7. Drug

    VidPrevtyn Beta

    go.drugbank.com/drugs/DB16427
    Approved

    [L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from … [A245829,L49696] In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.[L49691]

    Synonyms: SARS-CoV-2 prefusion Spike delta TM protein, recombinant (B.1.351 strain)
  8. Drug

    GRAd-COV2

    go.drugbank.com/drugs/DB16428
    Investigational

    This therapy is based on a novel replication-incompetent simian adenoviral vector that encodes the full-length SARS-CoV-2 spike protein (GRAd-COV2)[L30420, L30423]. … GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera[L30420, L30423].

  9. Drug

    CoVac-1

    go.drugbank.com/drugs/DB16429
    Investigational

    Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588]. … is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC))[L30428] and aims to induce broad T-cell

  10. Drug

    V590

    go.drugbank.com/drugs/DB16437
    Experimental

    By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose[L30583]. … Merck is currently underway to begin Phase I trials for the vaccine through intramuscular administration (NCT04569786).